Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma, Extranodal NK-T-Cell 2TMB-H 1Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 26Capecitabine 16Oxaliplatin 14Fluorouracil 13Cisplatin 12Leucovorin 9pembrolizumab 5Erlotinib Hydrochloride 5Bevacizumab 5durvalumab 4Trastuzumab 4Specimen Handling 4Sorafenib 4Magnetic Resonance Spectroscopy 4130-nm albumin-bound paclitaxel 4trifluridine tipiracil drug combination 3Lapatinib 3Irinotecan 3Carboplatin 3Biopsy 3tremelimumab 2toripalimab 2regorafenib 2lenvatinib 2dehydroftorafur 2cobimetinib 2atezolizumab 2anlotinib 2Nivolumab 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gallbladder Neoplasms × IMC-001 × Clear all
NCT03999658 2023-05-01

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Sorrento Therapeutics, Inc.

Phase 2 Withdrawn
GastrointestinalLymphoid

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Cholangiocarcinoma, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡